Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclotron-produced 99mTc for Thyroid and Bone Imaging
NCT02514187Completed
- Sponsor
- BC Cancer
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-blind trial of technetium-99m in hyperthyroidism, bone metastases, bone fracture and 1 more, sponsored by BC Cancer. Primary endpoint: Agreement rate of the blinded read of scintiscans at 12 weeks. Started Oct 2015; status: completed.
02
Drugs
technetium-99m
03
Conditions
hyperthyroidismbone metastasesbone fractureOsteitis
Beyond the preview
Go deeper on NCT02514187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514187.